Prognostic value of nutritional status in patients with human immunodeficiency virus infection-related lymphoma.

TingTing Liu, RenZhi Hu, Jing Lv, Qin Luo, LuXiang Xu, ChaoYu Wang, Jun Liu, ZaiLin Yang, LingLi Xu, Yao Liu
Author Information
  1. TingTing Liu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  2. RenZhi Hu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  3. Jing Lv: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  4. Qin Luo: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  5. LuXiang Xu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  6. ChaoYu Wang: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  7. Jun Liu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  8. ZaiLin Yang: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  9. LingLi Xu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Personnel Section, Chongqing University Cancer Hospital, Chongqing, China.
  10. Yao Liu: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.

Abstract

Objective: To investigate the predictive value of nutritional status on the prognosis of patients with human immunodeficiency virus (HIV) infection-related lymphoma.
Materials and methods: A total of 149 patients with HIV infection-related lymphoma who were admitted to our hospital from August 2012 to May 2022 were selected as research subjects. Based on the patient prognosis, they were divided into a poor prognosis group ( = 30) and a good prognosis group ( = 119). General data from patients in both groups were collected, and the nutritional status of the patients was evaluated using the Controlling Nutritional Status (CONUT) score. Factors affecting the prognosis of HIV infection-related lymphoma were analyzed using univariate and multivariate analyses, and a prediction model was developed based on the analyzed factors. The receiver operating characteristic (ROC) curve was used to analyze the prediction model of the CONUT score alone and included the CONUT score in the prognosis of patients with HIV infection-related lymphoma. The predictive value of the data was assessed, and a survival curve was drawn to compare the survival of patients with different nutritional statuses.
Results: There were significant differences in age, B symptoms, treatment conditions, International Prognostic Index (IPI), pathological stage, Eastern Collaborative Tumor Group physical status score (ECOG PS), CD4+ cell count, β2 microglobulin, and lactate dehydrogenase (LDH) between the poor prognosis group and the good prognosis group ( < 0.05). The CONUT score of the poor prognosis group was higher than that of the good prognosis group, and the difference was statistically significant ( < 0.05). A univariate analysis demonstrated that the age, B symptoms, treatment status, IPI, pathological stage, ECOG PS, CD4+ cell count, β2 microglobulin, LDH, and CONUT score were prognostic factors for patients with HIV infection-related lymphoma ( < 0.05). The results of a multivariate regression analysis demonstrated that the age, B symptoms, treatment status, IPI, pathological stage, ECOG PS, and CONUT score were independent risk factors for the prognosis of patients with HIV infection-related lymphoma ( < 0.05). The prediction model was constructed according to the multivariate Cox regression analysis results. The model formula was as follows: Logit() = -10.687 + 1.728 × age + 1.713 × B symptoms + 1.682 × treatment status + 1.810 × IPI + 1.643 × pathological stage + 1.584 × ECOG PS + 1.779 × CONUT score. The ROC curve was used to analyze the predictive value of the CONUT score alone and the predictive model including the CONUT score on the prognosis of patients with HIV infection-related lymphoma. The predictive value of the prognosis of patients with tumors was higher ( < 0.05). According to the results of the ROC curve analysis, the patients were divided into a high CONUT group (CONUT > 6.00 points, = 31) and a low CONUT group (CONUT ≤ 6.00 points, = 118) based on the Optimum threshold of the CONUT score. The survival curve showed that the survival rate of the high CONUT group was lower than that of the low CONUT group ( < 0.05).
Conclusion: The poor prognosis of HIV infection-related lymphoma is related to nutritional status, which is an independent risk factor affecting the prognosis of patients and can be used as a practical indicator to predict the prognosis of patients.

Keywords

References

Investig Clin Urol. 2021 Sep;62(5):553-559 [PMID: 34387033]
Niger J Clin Pract. 2021 Aug;24(8):1194-1199 [PMID: 34397030]
Gynecol Oncol. 2021 Sep;162(3):763-769 [PMID: 34148719]
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):203-208 [PMID: 35405777]
Turk J Med Sci. 2021 May 7;51(4):2112-2119 [PMID: 33957727]
Front Immunol. 2021 Nov 30;12:778746 [PMID: 34917092]
Front Oncol. 2022 Jan 13;11:798008 [PMID: 35096597]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):456-461 [PMID: 32654457]
Gan To Kagaku Ryoho. 2021 Dec;48(13):1975-1977 [PMID: 35045465]
Obes Surg. 2021 Aug;31(8):3715-3726 [PMID: 34031850]
Hematol Oncol. 2020 Aug;38(3):309-317 [PMID: 32223021]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Aug;36(4):446-9 [PMID: 25176216]
Leuk Lymphoma. 2022 Jun;63(6):1323-1330 [PMID: 34965828]
Front Immunol. 2021 Sep 03;12:700045 [PMID: 34539628]
Fujita Med J. 2022 May;8(2):59-64 [PMID: 35520290]
Clin Nutr. 2020 Aug;39(8):2564-2570 [PMID: 31787366]
Heart Vessels. 2021 Aug;36(8):1109-1116 [PMID: 33538856]
Gastric Cancer. 2018 Mar;21(2):204-212 [PMID: 28656485]
Surg Today. 2021 Jan;51(1):144-152 [PMID: 32623583]
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):685-688 [PMID: 32942826]
Bull Cancer. 2021 Oct;108(10):953-962 [PMID: 34246454]
World J Surg Oncol. 2021 Jan 23;19(1):25 [PMID: 33485347]
EJHaem. 2022 May 04;3(3):924-926 [PMID: 36051083]
Hematology. 2022 Dec;27(1):653-658 [PMID: 35622088]
Infect Drug Resist. 2021 Mar 18;14:1105-1113 [PMID: 33776456]
Nutr Hosp. 2005 Jan-Feb;20(1):38-45 [PMID: 15762418]

Word Cloud

Similar Articles

Cited By